Lindbrook Capital, LLC Sage Therapeutics, Inc. Transaction History

Lindbrook Capital, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$10.58 - $17.9 $2,761 - $4,671	261 Added 131.82%	459 $4,000
Q4 2023 Jan 31, 2024	SELL	$17.1 - $22.26 $1,368 - $1,780	-80 Reduced 28.78%	198 $4,000
Q3 2023 Oct 25, 2023	BUY	$16.75 - $48.98 $3,584 - $10,481	214 Added 334.38%	278 $5,000
Q2 2023 Jul 28, 2023	BUY	$40.65 - $59.54 $487 - $714	12 Added 23.08%	64 $3,000
Q1 2023 Apr 26, 2023	SELL	$37.27 - $46.57 $149 - $186	-4 Reduced 7.14%	52 $2,000
Q4 2022 Jan 24, 2023	SELL	$32.2 - $43.61 $5,699 - $7,718	-177 Reduced 75.97%	56 $0
Q3 2022 Nov 10, 2022	BUY	$32.28 - $43.27 $7,521 - $10,081	233 New	233 $9,000
Q2 2022 Aug 01, 2022	SELL	$27.52 - $37.99 $2,008 - $2,773	-73 Closed	0 $0
Q1 2022 Apr 21, 2022	BUY	$30.71 - $45.71 $2,241 - $3,336	73 New	73 $2,000
Q4 2021 Jan 18, 2022	SELL	$37.06 - $47.11 $2,038 - $2,591	-55 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$40.26 - $57.37 $603 - $860	15 Added 37.5%	55 $2,000
Q2 2021 Jul 27, 2021	SELL	$54.88 - $79.29 $658 - $951	-12 Reduced 23.08%	40 $2,000
Q2 2020 Jul 27, 2020	BUY	$25.95 - $43.15 $1,349 - $2,243	52 New	52 $2,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.